Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

STRO vs EQ: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EQ Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 4–5 Matrix Metrics)

EQ Overall Winner 6-Pillar Tally: STRO 1 – 4 EQ (1 Tie) Matrix Metrics: STRO 5 – 4 EQ

As of Nov 19, 2026, Equillium, Inc. (EQ) is the stronger overall head-to-head candidate over Sutro Biopharma, Inc. (STRO) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). STRO carries a Unified Composite Score of 54.9/100 (HOLD) at $8.72 (10.0x Forward P/E, -254.7% operating margin), whereas EQ carries 48.0/100 (HOLD) at $1.12 (1.5x Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While STRO currently prints a higher short-term Unified Composite Score (54.9/100 HOLD vs. EQ 48.0/100 HOLD), EQ captures the overall institutional head-to-head verdict (4–5 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -254.7% operating margin) and revenue trajectory (-52.3% vs. -6.1% YoY).
  • Technical & Structure Timing Caution: STRO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.2); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About STRO vs EQ
STRO NASDAQ
Sutro Biopharma, Inc.
Biological Products, (No Diagnostic Substances)
$8.72
+2.59% 1D
Market Cap $141.1M
TTM Revenue $45M
Forward P/E 10.0x
Beta / 30D Vol 1.58β · 77% Vol
Unified Composite Score
54.9 / 100 HOLD
Tech 65.0 Fund 51.0 Flow 50.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -26.6%), weak momentum, RSI 35
RSI-14: 35.2 · SMA20: $9.40 · SMA50: $12.38
EQ NASDAQ Head-to-Head Winner
Equillium, Inc. Common Stock
Pharmaceutical Preparations
$1.12
+1.82% 1D
Market Cap $90.6M
TTM Revenue $4.4M
Forward P/E 1.5x
Beta / 30D Vol 1.53β · 93% Vol
Unified Composite Score
48.0 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 63.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -20.8%), weak momentum, RSI 36
RSI-14: 36.0 · SMA20: $1.33 · SMA50: $1.49

6-Pillar Scorecard Institutional Category Breakdown (STRO 1 – 4 EQ)

Columns: Metric · STRO · EQ
1. Valuation Multiples EQ
Forward P/E 10.0x 1.5x
Trailing P/E 10.0x 1.5x
PEG Ratio N/M N/M
EV / Revenue 3.1x 7.7x
2. Growth & Scale STRO
Revenue Growth (YoY) -6.1% -52.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $45M $4.4M
Market Cap $141.1M $90.6M
3. Profitability & Quality EQ
Gross Margin N/A 100.0%
Operating Margin -254.7% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -1810.0% -59.0%
4. Balance Sheet & Cash Flow EQ
Cash Generation (TTM) -$109M EBITDA -$20M
Cash Flow Margin N/A N/A
Net Cash / Leverage -1810.0% ROE $57M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EQ
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 122.4% (<1st %ile) 261.3% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: STRO (5) vs EQ (4)
Institutional Metric STRO EQ Criterion Row Edge
Market Capitalization
Scale
$141.1M $90.6M Larger Scale STRO
Trailing P/E Ratio
Valuation
10.0x 1.5x Lower Multiple EQ
Forward P/E Ratio
Valuation
10.0x 1.5x Lower Multiple EQ
Revenue Growth (YoY)
Growth
-6.1% -52.3% Higher Growth STRO
Operating Margin (TTM)
Profitability
-254.7% 0.0% Higher Margin EQ
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-1810.0% -59.0% Higher ROE EQ
52-Week Range Position
Momentum
18% ($1–$44) 11% ($1–$4) Stronger Trend STRO
Beta / 30D Volatility
Risk Regime
1.58β · 77% Vol 1.53β · 93% Vol Lower Realized Risk STRO
Unified Institutional Score
Composite Signal
54.9 / 100 (HOLD) 48.0 / 100 (HOLD) Higher Composite STRO
Trailing 12M Revenue (USD)
Operating Scale
$45M $4.4M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.1x EV/Rev N/M PEG · 7.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$109M EBITDA (-1810.0% ROE) -$20M ($57M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon STRO +1.95 pp
STRO: -19.18% · EQ: -21.13%
3M Horizon EQ +7.04 pp
STRO: -58.56% · EQ: -51.52%
6M Horizon EQ +22.2 pp
STRO: -71.52% · EQ: -49.32%
1Y Horizon STRO +867.78 pp
STRO: +879.78% · EQ: +12.0%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on STRO vs EQ. Trailing 12-month operating profitability (STRO -254.7% vs EQ 0.0%) and valuation multiples (STRO 10.0x vs EQ 1.5x Forward P/E) are benchmarked directly in Pillar 4 below.

STRO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$45M
Gross MarginN/A
Op. Margin-254.7%
ROE / Fwd P/E-1810.0% · 10.0x
EQ ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.4M
Gross Margin100.0%
Op. Margin0.0%
ROE / Fwd P/E-59.0% · 1.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
STRO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 122.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact STRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EQ UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 261.3%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EQ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
STRO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $141.1M market capitalization and -254.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EQ Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $90.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ STRO vs EQ Key Questions & Quantitative Answers

As of Nov 19, 2026, Equillium, Inc. (EQ) is the stronger overall head-to-head candidate over Sutro Biopharma, Inc. (STRO) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). STRO carries a Unified Composite Score of 54.9/100 (HOLD) at $8.72 (10.0x Forward P/E, -254.7% operating margin), whereas EQ carries 48.0/100 (HOLD) at $1.12 (1.5x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While STRO currently prints a higher short-term Unified Composite Score (54.9/100 HOLD vs. EQ 48.0/100 HOLD), EQ captures the overall institutional head-to-head verdict (4–5 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -254.7% operating margin) and revenue trajectory (-52.3% vs. -6.1% YoY). Technical & Structure Timing Caution: STRO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.2); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

STRO leads the Growth & Scale pillar: STRO posts -6.1% YoY revenue growth and +0.0% YoY earnings growth on $45M TTM revenue (N/A gross margin, -254.7% operating margin), compared with EQ at -52.3% YoY revenue growth and +0.0% YoY earnings growth on $4.4M TTM revenue (100.0% gross margin, 0.0% operating margin). On trailing 12-month operating scale, STRO generates $45M in USD-normalized revenue versus $4.4M for EQ. In operating R&D and SG&A reinvestment, STRO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EQ.

EQ screens cheaper on headline valuation multiples. STRO trades at 10.0x Forward P/E, 10.0x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (unreported EBITDA margin), whereas EQ trades at 1.5x Forward P/E, 1.5x Trailing P/E, N/M PEG, and 7.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against STRO (-1810.0% ROE) versus EQ (-59.0% ROE) capital efficiency.

In options market volatility and institutional positioning, STRO carries 122.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.58β · 77% Vol realized risk). By comparison, EQ carries 261.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.53β · 93% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.